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Introduction: Whole-body ischemia and reperfusion trigger a systemic inflammatory response. In this study, we
analyzed the effect of temperature on the inflammatory response in patients treated with prolonged mild
hypothermia after cardiac arrest.
Methods: Ten comatose patients with return of spontaneous circulation after pulseless electrical activity/asystole or
prolonged ventricular fibrillation were treated with mild therapeutic hypothermia for 72 hours after admission to a
tertiary care university hospital. At admission and at 12, 24, 36, 48, 72, 96 and 114 hours, the patients’ temperature
was measured and blood samples were taken from the arterial catheter. Proinflammatory interleukin 6 (IL-6) and
anti-inflammatory (IL-10) cytokines and chemokines (IL-8 and monocyte chemotactic protein 1), intercellular adhesion
molecule 1 and complement activation products (C1r-C1s-C1inhibitor, C4bc, C3bPBb, C3bc and terminal complement
complex) were measured. Changes over time were analyzed with the repeated measures test for nonparametric data.
Dunn’s multiple comparisons test was used for comparison of individual time points.
Results: The median temperature at the start of the study was 34.3°C (33.4°C to 35.2°C) and was maintained between
32°C and 34°C for 72 hours. All patients were passively rewarmed after 72 hours, from (median (IQR)) 33.7°C (33.1°C to
33.9°C) at 72 hours to 38.0°C (37.5°C to 38.1°C) at 114 hours (P <0.001). In general, the cytokines and chemokines
remained stable during hypothermia and decreased during rewarming, whereas complement activation was
suppressed during the whole hypothermia period and increased modestly during rewarming.
Conclusions: Prolonged hypothermia may blunt the inflammatory response after rewarming in patients after cardiac
arrest. Complement activation was low during the whole hypothermia period, indicating that complement activation is
also highly temperature-sensitive in vivo. Because inflammation is a strong mediator of secondary brain injury, a blunted
proinflammatory response after rewarming may be beneficial.Introduction
Induced hypothermia confers a neuroprotective effect in
comatose cardiac arrest patients after return of spontan-
eous circulation (ROSC) [1,2]. The results of clinical and
experimental studies demonstrate a multifactorial neuro-
protective effect of hypothermia during and after an is-
chemic insult by simultaneous suppression of multiple
damaging pathways [3,4].* Correspondence: laurens.bisschops@radboudumc.nl
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unless otherwise stated.The post–cardiac arrest phase is characterized by high
levels of circulating cytokines and adhesion molecules, the
presence of plasma endotoxins, and dysregulated leukocyte
production of cytokines and complement activation. The
mechanisms underlying this postresuscitation disease in-
volve a whole-body ischemia and reperfusion syndrome
that triggers a systemic inflammatory response mimicking
the immunologic and coagulation disorders observed in se-
vere sepsis [5]. Although reperfusion is essential for ultim-
ate tissue survival, it may exacerbate cerebral injury and
thus presents a treatment paradox [6]. Mild hypothermia
inhibits inflammation after experimental stroke and brainral Ltd. This is an Open Access article distributed under the terms of the Creative
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on Resuscitation advises mild hypothermia for 12 to
24 hours in comatose patients after cardiac arrest [9].
In a previous study, we demonstrated that complement
activation and a proinflammatory response occur during
rewarming after 24-hour induction of mild hypothermia
after cardiac arrest [10]. The results of that study suggested
a strong temporal relationship between inflammatory pa-
rameters and hypothermia and subsequent rewarming;
however, because of the observational study design (a nor-
mothermic control group was considered unethical),
it was not possible to establish a causal effect between
temperature and inflammation. The aim of the present
study was to analyze the effect of temperature on the
inflammatory response after cardiac arrest. We describe
the inflammatory response over time in patients treated
with therapeutic hypothermia for an extended period of
72 hours after cardiac arrest.
Material and methods
Study population
We performed a prospective observational study in ten
comatose patients successfully resuscitated from out-of-
hospital cardiac arrest. Prolonged mild therapeutic
hypothermia (MTH) (72 hours) is a standard of care in
our ICU for comatose patients with ROSC after asystole,
pulseless electrical activity (PEA) or resistant ventricular
fibrillation (VF). The study was carried out in the Radboud
University Medical Centre (UMC), a tertiary care hos-
pital in the Netherlands, after we received approval
from the local institutional review board (Commissie
Mensgebonden Onderzoek (CMO) Radboud UMC). The
CMO Radboud UMC waived the need for informed con-
sent for the withdrawal of small amounts of blood for re-
search purposes, because this small amount of blood
withdrawn from an arterial catheter does not cause any
discomfort or harm to the patient. All legal representa-
tives of the patients were informed about the study de-
tails. The study was performed according to the guidelines
of the National Institutes of Health and in accordance with
the Declaration of Helsinki and its later amendments.
All patients 18 years of age or older were eligible for the
study if they met the following criteria: (1) comatose state
(Glasgow Coma Scale score ≤6) after ROSC and (2) ROSC
after asystole, PEA or VF with prolonged (>30 minutes)
cardiopulmonary resuscitation. The following were the
exclusion criteria: (1) pregnancy; (2) thrombolytic therapy;
(3) refractory cardiogenic shock, despite the use of vaso-
pressors and/or inotropic agents, compromising cerebral
blood flow, which was one of the study objectives
during prolonged hypothermia [11]; (4) life expect-
ancy <24 hours; (5) hypoxemia, defined as arterial oxy-
gen saturation (SaO2) <90%; (6) chronic renal failure
(creatinine >200 μmol/L); (7) chronic liver failure; and (8)known preexisting neurological disease. The time between
collapse and ROSC, the start of cooling and the start of
the experiment were calculated based on data provided by
the paramedic team.
Patient management
All patients were admitted to the ICU of a tertiary care
university hospital in Nijmegen, The Netherlands. If
necessary, a coronary angiogram was obtained and percu-
taneous coronary intervention was performed before
admission to the ICU. In agreement with our local proto-
col, all patients were cooled to 32°C to 34°C by rapid infu-
sion of 30 ml/kg body weight of cold Ringer’s lactate at
4°C, followed by external cooling using two water-
circulating blankets (Blanketrol II hyper-hypothermia sys-
tem; Cincinnati Sub-Zero, Tilburg, The Netherlands).
Patients’ body temperature was measured continuously
with a rectal temperature probe (YSI Incorporated 401,
Van de Putte Medical, Nieuwegein, The Netherlands) and
maintained at 32°C to 34°C for 72 hours, followed by pas-
sive rewarming to normothermia (defined as 36.5°C). All
patients were sedated with midazolam and/or propofol
and sufentanil during hypothermia. Sedation and analge-
sics were stopped as soon as the body temperature
was ≥36.5°C. In cases of shivering, patients received an
intravenous bolus injection of rocuronium.
All patients were intubated and mechanically venti-
lated with the aim of maintaining partial pressure of
arterial oxygen (PaO2) >75 mmHg and partial pressure
of arterial carbon dioxide (PaCO2) between 34 and
42 mmHg. α-Stat was used for pH maintenance. The ra-
dial or femoral artery was cannulated for monitoring of
blood pressure and sampling of arterial blood. A central
venous catheter was inserted into the internal jugular vein
for administration of drugs. According to our local proto-
col, mean arterial blood pressure was maintained between
80 to 100 mmHg, and diuresis was aimed at achiev-
ing >0.5 ml/kg/hr. If necessary, patients were treated with
volume infusion and dobutamine and/or (nor)epinephrine.
Serum concentrations of sodium, potassium, magne-
sium and phosphate were maintained within the normal
ranges. All patients were treated with continuous insulin
infusion therapy aimed at maintaining blood glucose levels
between 6.0 and 8.0 mmol/L. The hemoglobin concentra-
tion was kept ≥6.0 mmol/L.
Data collection and blood sampling
Demographic and prehospital data were collected upon
admission. Hemodynamic parameters, temperature and
SaO2 were measured continuously. Upon admission and
every 12 hours until 114 hours after admission, blood
samples anticoagulated with ethylenediaminetetraacetic
acid were taken from the arterial catheter. Blood samples
were immediately centrifuged for 15 minutes at 2,000 g
Table 1 Demographic dataa
Demographics Data
Males, n (%) 9 (90%)
Age, yr 66.0 (62.3 to 72.8)
Body mass index, kg/m2 26.0 (25.0 to 26.0)
Time between collapse and ROSC, min 30.0 (25.0 to 33.8)
Time between collapse and start of cooling, min 120 (120 to 155)
Time between collapse and start of study, min 180 (150 to 200)
SAPS II 72.5 (68.5 to 77.8)
APACHE II score 30.0 (27.5 to 33.8)
pH upon ED arrival 7.15 (6.93 to 7.23)
BE upon ED arrival, mmol/L −13.4 (−17.1 to −8.1)
Lactate upon ED arrival, mmol/L 9.8 (5.6 to 13.0)
PaCO2 upon ED arrival, mmHg 40.5 (36.7 to 45.0)
Patients who died, n (%) 6 (60%)
aAPACHE II: Acute Physiology and Chronic Health Evaluation II; BE: Base Excess;
ED: Emergency department; ROSC: Return of spontaneous circulation; SAPS II:
Simplified Acute Physiology Score II. Data are expressed as median values (IQR).
Figure 1 Temperature changes over time. Values represent
medians (black lines in boxes), 25th and 75th interquartile ranges
(boxes) and minimums and maximums (whiskers).
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batchwise analysis.
Measurement of cytokines, chemokines, adhesion
molecules and complements
Concentrations of interleukin 6 (IL-6), IL-10, IL-8 and
monocyte chemotactic protein 1 (MCP-1) were mea-
sured using a simultaneous Luminex assay according
to the manufacturer’s instructions (MILLIPLEX; EMD
Millipore, Billerica, MA, USA). Concentrations of inter-
cellular adhesion molecule 1 (ICAM-1) and vascular cell
adhesion molecule 1 (VCAM-1) were measured using a
simultaneous Luminex assay according to the manufac-
turer’s instructions (Bio-Rad Laboratories, Hercules, CA,
USA). The complement activation products C1r-C1s-C1
inhibitor (C1rs-C1inh) complex (classical pathway),
C4bc (classic and lectin pathway), C3bPBb (alternative
pathway), C3bc (common pathway) and the soluble ter-
minal complement complex (TCC) were measured using
enzyme-linked immunosorbent assays based on monoclo-
nal antibodies directed against neoepitopes of the prod-
ucts and performed according to a protocol described in
detail previously [12]. Values are expressed as arbitrary
units per milliliter (AU/ml) related to a standard of hu-
man serum activated with zymosan, defined to contain
1,000 AU/ml.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5.0 software (GraphPad Software, La Jolla, CA,
USA) and Excel 2007 (Microsoft, Redmond, WA, USA).
Data are presented as medians with 25th and 75th per-
centiles. The figures show median values as black lines
in boxes, 25th to 75th interquartile ranges as boxes,
and minimums and maximums as whiskers. Changes
over time were analyzed with the repeated measures
test for nonparametric data. Dunn’s multiple compari-
sons test was used for comparison of individual time




We studied ten comatose patients successfully resusci-
tated from an out-of-hospital cardiac arrest. Data on
cerebral blood flow and cerebral oxygen extraction in
this cohort of patients have been published previously
[11]. The demographic data of the patients are shown in
Table 1. The primary rhythm was asystole in four pa-
tients, VF in four patients and PEA in two patients. Six
patients died in the ICU, three due to circulatory failure
during rewarming and two because of severe postanoxic
brain damage. One patient admitted to the ICU after
PEA regained consciousness, but active treatment waswithdrawn because of preexisting severe chronic respira-
tory failure. None of the patients died during the 72-
hour period of cooling.
Clinical data
The patients’ median body temperature at the start of
the study was 34.3°C (33.4°C to 35.2°C) and was main-
tained between 32°C and 34°C for 72 hours. All patients
were passively rewarmed after 72 hours from 33.7°C
(33.1°C to 33.9°C) at 72 hours to 38.0°C (37.5°C to 38.1°C)
at 114 hours after admission (P <0.001) (Figure 1). The
median (±SEM) rewarming rate was 0.27 ± 0.03°C/hr.
Norepinephrine was used in all patients, and dobutamine
was added in seven patients. Administration of epineph-
rine was necessary in two patients. The median PaCO2
Figure 3 Interleukin 10 levels during hypothermia and after
rewarming. Graph shows levels of the anti-inflammatory cytokine
interleukin 10 (IL-10) in arterial blood samples from ten patients
during hypothermia (0 to 72 hours) and after rewarming (72 to
114 hours). Values are medians (black lines in boxes), 25th to 75
interquartile ranges (boxes) and minimums and maximums (whiskers).
*Statistically significant compared to time 0.
Bisschops et al. Critical Care 2014, 18:546 Page 4 of 8
http://ccforum.com/content/18/5/546was 40.5 mmHg (36.7 to 45.0) upon admission and did
not change significantly throughout the study period
(P = 0.980). The median PaO2 was >75 mmHg throughout
the study period.
Cytokines and chemokines
The median IL-6 concentration at the start of the study
was 118 pg/ml (IQR = 55 to 359), then decreased signifi-
cantly to 19.5 pg/ml (IQR = 8.8 to 83.7) at 96 hours and
to 6.7 pg/ml (IQR = 1.7 to 51) at 114 hours (P = 0.0018)
(Figure 2a). The median IL-8 concentration at the start
of the study was 184 pg/ml (IQR = 61 to 446) and de-
creased significantly to 15 pg/ml (IQR = 1.24 to 32) at
114 hours (P = 0.0102) (Figure 2b). The median MCP-1
concentration at the start of the study was 2,158 pg/ml
(IQR = 724 to 10,493), then decreased significantly to
503 pg/ml (IQR = 310 to 881) at 96 hours and to
240 pg/ml (IQR = 45 to 1,166) at 114 hours (P = 0.0006)
(Figure 2c). The median IL-10 concentration at the start
of the study was 517 pg/ml (IQR = 269 to 1,796), then
decreased significantly to 8.3 pg/ml (IQR = 3.6 to 394) at
72 hours and to 3.7 pg/ml (IQR = 2.6 to 5.1) at 114 hours
(P <0.001) (Figure 3). There were no differences in cyto-
kine or chemokine concentrations between survivors and
nonsurvivors (data not shown).
Adhesion molecules
The median ICAM-1 concentration increased signifi-
cantly from 130 ng/ml (108 to 162) at 0 hours to 237 ng/mlFigure 2 Cytokine and chemokine profiles of the patients during hyp
after cardiac arrest with respect to the proinflammatory cytokine interleukin
protein 1 (MCP-1) (c) during hypothermia (0 to 72 hours) and after rewarm
boxes), 25th to 75th interquartile ranges (boxes) and minimums and maxim(167 to 370) at 72 hours and 175 ng/ml (137 to 265) at
114 hours (P <0.0166) (Figure 4). The median VCAM-1
concentration was 170 ng/ml (156 to 196) at admission
and decreased significantly from 228 ng/ml (174 to 262)
at 48 hours to 147 ng/ml (130 to 177) at 72 hours and
remained stable during the rest of the observation period
(P = 0.001) (data not shown). There were no differences in
adhesion molecule concentrations of ICAM-1 or VCAM-
1 between survivors and nonsurvivors (data not shown).othermia and after rewarming. Graphs show data for ten patients
6 (IL-6) (a) and the chemokines IL-8 (b) and monocyte chemotactic
ing (72 to 114 hours). Values presented are medians (black lines in
ums (whiskers). *Statistically significant compared to time 0.
Figure 4 Intercellular adhesion molecule 1 concentrations
during hypothermia (0 to 72 hours) and after rewarming
(72 to 114 hours) in ten patients after cardiac arrest. The
medians (black lines in boxes), 25th and 75th interquartile ranges
(boxes) and minimums and maximums (whiskers) are depicted for
soluble intercellular adhesion molecule 1 in arterial samples (sICAM).
*Statistically significant difference compared to time 0.
Figure 5 Terminal complement complex during hypothermia
(0 to 72 hours) and after rewarming (72 to 114 hours) in ten
patients after cardiac arrest. The medians (black lines in boxes),
25th and 75 interquartile ranges (boxes) and minimums and
maximums (whiskers) are depicted for arterial samples. *Statistically
significant difference compared to time 0. #Statistically significant
difference compared to 72 hours. TCC: Terminal complement
complex (terminal pathway).
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The median C1rs-C1inh concentration was 9.8 AU/ml
(7.0 to 11) upon admission and decreased to 7.2 AU/ml
(5.0 to 12) at 72 hours, followed by a significant increase
during rewarming to 9.4 AU/ml (7.4 to 17) at 114 hours
(P = 0.0283). The median C4bc concentration decreased
from 14 AU/ml (9.3 to 66) at the start of the study to
8.5 AU/ml (7.1 to 19) at 72 hours, followed by a nonsig-
nificant increase to 11 AU/ml (8.4 to 20) (P = 0.6361).
The median C3bPBb concentration decreased signifi-
cantly from 97 AU/ml (32 to 136) upon admission to
23 AU/ml (15 to 94) at 72 hours and 17 AU/ml at
114 hours (15 to 39) (P = 0.0179). The median C3bc
concentration decreased by a trend from 36 AU/ml
(11 to 89) upon admission to 9.1 AU/ml at 72 hours
(5.0 to 51) and 8.3 AU/ml (6.3 to 15) at 114 hours (P =
0.0619). The median end product TCC concentration was
1.3 AU/ml (0.9 to 5.1) at admission, decreased signifi-
cantly during hypothermia to 0.5 AU/ml (0.4 to 0.7) at
72 hours and increased significantly during rewarming to
1.1 AU/ml (0.7 to 1.6) at 114 hours (P <0.001) (Figure 5).
There were no differences in concentrations of the com-
plement products between survivors and nonsurvivors
(data not shown).
Comparison of our present results with the results of
our previous study describing complement activation
and the proinflammatory response during rewarming
after 24 hours of MTH was not possible, owing to differ-
ent patient characteristics between the studies [10].
Discussion
This study demonstrates that hypothermia may affect the
inflammatory response after cardiac arrest in two ways.First, after prolonged hypothermia, proinflammatory cyto-
kine activation during rewarming was absent. Second,
with prolonged exposure to MTH, complement activation
was low during the whole MTH period. These results in-
dicate that hypothermia may have a significant impact on
important markers of ischemia–reperfusion injury in pa-
tients after cardiac arrest.
The proinflammatory cytokine IL-6 remained stable
during 72 hours of MTH and decreased after rewarming.
This finding is in contrast to the rise in IL-6 during
rewarming after 24 hours of hypothermia [10]. The pro-
inflammatory chemokines IL-8 and MCP-1, as well as
the anti-inflammatory cytokine IL-10, also decreased
during 72 hours of MTH and rewarming. These data
suggest that a proinflammatory effect of rewarming is
mitigated after prolonged hypothermia. Currently, only
a small number of studies have been conducted in which
researchers measured inflammatory mediators during
hypothermia and rewarming, and these studies pro-
duced conflicting results and involved different types
of acute brain injury, possibly with similar pathophy-
siogical bases [13].
MTH resulted in decreased mRNA expression of typ-
ical cerebral inflammatory mediators (IL-1β, IL-6, IL-10,
tumor necrosis factor α and ICAM-1) after experimental
VF in pigs [14]. However, in a clinical study, Fries et al.
demonstrated significantly increased systemic IL-6 levels
[15]. Altogether, these studies were focused on the in-
flammatory response during hypothermia, not during
rewarming. The proinflammatory response of rewarming
has been described in a number of animal models and in
patients with traumatic brain injury. Hypothermia and
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of trauma, hemorrhage and subsequent fracture fixation
[16]. Rewarming before fracture stabilization was associ-
ated with more pronounced IL-6 and MCP-1 increases
without affecting the anti-inflammatory response. In a rat
model of mild hypothermia and hemorrhagic shock,
rewarming resulted in higher synthesis of reactive oxygen
species from peritoneal phagocytes and increased circulat-
ing levels of nitric oxide, with no effects on pro- or anti-
inflammatory cytokine production [17]. Hypothermia
decreased IL-6 concentrations in patients after severe
traumatic brain injury [18], similar to the findings in
our present study. Rewarming of patients with brain in-
jury after 4 to 9 days of hypothermia resulted in a further
decrease in IL-6 in patients whose clinical course im-
proved. In contrast, rewarming increased IL-6 concentra-
tions in patients with poor outcomes. This differential
response of IL-6 to rewarming in patients with a poor or
favorable outcome could not be determined in our cohort
of patients, which is probably due to the small number of
patients or the different underlying pathophysiology (brain
death versus cardiac arrest).
A number of mechanisms may explain the blunted pro-
inflammatory response on rewarming after prolonged
hypothermia. Hypothermia has been reported to decrease
leukocyte count and function, and prolonged hypothermia
has been linked to a sustained impairment of neutrophil
function. Neutrophil and monocyte chemotaxis, migra-
tion, phagocytosis and oxidative metabolism in vitro were
markedly reduced at 29°C versus 37°C. Neutrophil oxida-
tive function is impaired at 33°C in vivo [19]. Alternatively,
we hypothesize that an anti-inflammatory response is
mounted simultaneously with the proinflammatory re-
sponse, presumably to curtail inflammation and prevent
collateral tissue damage. This anti-inflammatory response
may be comparable to the immunoparalytic effect seen in
septic patients [20]. Reduced monocyte and leukocyte ac-
tivity may thus result in failure to induce a proinflamma-
tory reaction at day 3 after cardiac arrest.
ICAM-1 is an endothelial adhesion molecule of the
immunoglobulin gene superfamily and is involved in the
cascade of leukocyte rolling on the activated endothelial
blood vessel walls, neutrophil activation, adherence to
endothelial cells and transmigration into the interstitium.
Our present study confirms that ischemia–reperfusion
injury such as that found in cardiac arrest survivors
induces ICAM-1 concentration in both humans and la-
boratory animals [10,21-25]. We previously measured a sig-
nificant increase in plasma ICAM-1 during a modest
increase in temperature during rewarming after 24 hours of
MTH [10]. However, after 72 hours of MTH, no subsequent
increase in ICAM-1 was measured during rewarming,
suggesting a blunted inflammatory response during pro-
longed hypothermia. This suppressed ICAM-1 productionis most likely the result of hypothermia-mediated, de-
creased ICAM-1 production at the transcriptional level
[7,8,26]. As ICAM-1 expression is enhanced by proinflam-
matory cytokines, the production of ICAM-1 will be fur-
ther reduced in these patients because proinflammatory
stimulation of ICAM-1 is diminished during hypothermia.
Complement is an important component of the innate
immune system and a key player in ischemia–reperfusion
injury [6,27]. Böttiger et al. demonstrated significant sys-
temic increases in the complement activation products
C3a and SC5b-9 (TCC) during resuscitation and early re-
perfusion in adult humans, which returned to baseline
levels within 48 hours after ROSC [21]. Complement acti-
vation is largely temperature-dependent in vitro. The
slow, ongoing, spontaneous hydrolysis of the alterna-
tive pathway is efficiently inhibited by lowering the
temperature. This would also be the case in vivo. Thus,
during hypothermia, the concentration of activation prod-
ucts was reduced, including TCC, the terminal compo-
nent of complement activation. Rewarming after 72 hours
resulted in reactivation of the complement system with in-
creased TCC concentrations and certain other activation
products. Our results show that prolonged hypothermia
seemed to suppress complement activation during the
whole hypothermia period. The increased complement ac-
tivity seen during rewarming was most likely caused by
the increase in temperature per se. A possible additional
effect induced by circulatory molecules activating the
system cannot be excluded, but this activation was not ac-
companied by an inflammatory response, as discussed
above for the cytokines.
The present study has several limitations. The number
of studied patients is small. This may have contributed
to the wide range in concentrations of various cytokines,
chemokines and other proteins. It also suggests variable
inflammatory profiles among the ten included patients.
This could be related to heterogeneity in genetic factors
of the immune system and/or to the variation in dur-
ation until ROSC. A longer duration of resuscitation
leads to more ischemia–reperfusion damage and a sub-
sequent stronger immunological response. The different
pathophysiological mechanisms leading to the arrest of
circulation (PEA, VF, ventricular tachycardia, asystole)
could also have played a confounding role by affecting
the inflammatory response. However, we found no dif-
ferences in the immune response between different pri-
mary rhythms.
We describe several strong temporal relationships
between activation of the innate immune system and
hypothermia and rewarming. The study design (a lon-
gitudinal observational study without a control group)
prohibits definite conclusions about the causal relation-
ship between temperature and activation of the innate im-
mune response after cardiac arrest. We included patients
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arrest. Compared to our previous study that included only
patients after out-of-hospital VF, these patients had stron-
ger ischemia–reperfusion responses, reflected by higher
Simplified Acute Physiology Score II scores, higher Acute
Physiology and Chronic Health Evaluation II scores and
higher lactate levels upon admission [28]. This more
severe ischemia–reperfusion reaction induced a stronger
inflammatory reaction. This difference in patient charac-
teristics complicates a (quantitative) comparison between
24 and 72 hours of MTH. Vasopressors are frequently
used in patients after cardiac arrest to improve the (cere-
bral) perfusion pressure and avoid secondary ischemic in-
jury. Norepinephrine is the main neurotransmitter of the
central nervous system and can alter lymphoid functions.
β-adrenergic receptors are present on lymphoid cells,
and the stimulation of these receptors can affect the im-
mune response. Norepinephrine increases the production
of both pro- and anti-inflammatory cytokines and may shift
the cytokines toward a more anti-inflammatory profile
[29,30]. The use of catecholamines may have influenced
the results of our study by suppressing the inflammatory
response, which may have resulted in an underestimation
of the inflammatory response during rewarming.
Conclusion
Prolonged hypothermia may blunt the inflammatory
response after rewarming in patients after cardiac ar-
rest. Complement activation was low during the whole
hypothermia period, indicating that complement activa-
tion is highly temperature-sensitive also in vivo. As in-
flammation is a strong mediator of secondary brain injury,
a blunted proinflammatory response after rewarming may
be beneficial. Further research is required to explore the
benefits of MTH with regard to the optimal duration of
MTH and the optimal timing and rate of rewarming.
Key messages
 Prolonged hypothermia blunts the inflammatory
response after rewarming in patients after cardiac
arrest.
 Complement activation is efficiently attenuated
during prolonged MTH, indicating that complement
activation is highly temperature-sensitive in vivo.
 Because inflammation is a strong mediator of
secondary brain injury, a blunted proinflammatory
response after rewarming may be beneficial in
cardiac arrest patients.Abbreviations
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